- Initial clinical data expected in the second half of 2025 from this first-of-its-kind trial to administer a targeted radiotherapy conditioning agent with a commercial CAR-T therapy - Iomab-ACT ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results